NCT06692452 2026-04-01
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Withdrawn
Clinical Trials
128 trialsNCT06313996 2026-03-18
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Withdrawn
NCT05170828 2026-02-24
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Ossium Health, Inc.
Phase 1 Withdrawn
NCT05566223 2026-02-23
CheckCell-2
Intima Bioscience, Inc.
Phase 1/2 Withdrawn
NCT06829199 2026-02-19
MK-5890-003
Merck Sharp & Dohme LLC
Phase 2 Withdrawn
NCT06626256 2025-12-24
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
Phase 1 Withdrawn
NCT06690281 2025-09-11
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT06009107 2025-08-08
B-ALL
Juventas Cell Therapy Ltd.
Phase 1/2 Withdrawn
NCT05678205 2025-07-30
A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
Artiva Biotherapeutics, Inc.
Phase 1/2 Withdrawn
NCT06190249 2025-06-05
LN-144
Case Comprehensive Cancer Center
Phase 1 Withdrawn
NCT06572631 2025-05-25
Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor
City of Hope Medical Center
Phase 1 Withdrawn
NCT02548468 2025-05-02
Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma
Thomas Jefferson University
Phase 1 Withdrawn
NCT04418219 2025-04-29
Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer
Thomas Jefferson University
Phase 1/2 Withdrawn
NCT06094842 2025-04-01
Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer
Fred Hutchinson Cancer Center
Phase 1 Withdrawn
NCT05714306 2025-03-05
CHUV-OVACURE
Centre Hospitalier Universitaire Vaudois
Phase 1/2 Withdrawn
NCT03169764 2025-02-24
QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03169790 2025-02-24
QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03167164 2025-02-21
QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03167177 2025-02-21
QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03169738 2025-02-21
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03169777 2025-02-21
QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03175666 2025-02-21
QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03197571 2025-02-21
QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03197584 2025-02-21
QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03554109 2025-02-21
TNBC
ImmunityBio, Inc.
Phase 2 Withdrawn
NCT03563144 2025-02-21
QUILT-3.088: NANT Pancreatic Cancer Vaccine
ImmunityBio, Inc.
Phase 2 Withdrawn
NCT03574649 2025-02-21
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
ImmunityBio, Inc.
Phase 2 Withdrawn
NCT03647423 2025-02-21
QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT06341647 2025-01-24
Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201
GC Cell Corporation
Phase 1 Withdrawn
NCT06003179 2024-11-12
LOKI
University Health Network, Toronto
Phase 1 Withdrawn
NCT05177796 2024-10-24
Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT01843868 2024-08-07
Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Australasian Leukaemia and Lymphoma Group
Phase NA Withdrawn
NCT06210750 2024-05-17
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT05950113 2024-05-01
CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn
NCT05895201 2024-04-29
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
Indiana University
Phase 1/2 Withdrawn
NCT06205290 2024-04-02
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Withdrawn
NCT04102436 2024-03-12
Non-Viral TCR Gene Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT04220008 2024-01-12
Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT04029038 2023-08-21
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT05934097 2023-07-06
FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
Fate Therapeutics
Phase 1 Withdrawn
NCT05513612 2023-03-01
Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
Shanghai Pudong Hospital
Phase 1 Withdrawn
NCT05531708 2023-03-01
Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors
Shanghai Pudong Hospital
Phase 1 Withdrawn
NCT04282174 2022-09-27
2019-KOE-001
Baptist Health South Florida
Phase 2 Withdrawn
NCT04762901 2022-04-26
LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer
Wake Forest University Health Sciences
Phase 1 Withdrawn
NCT04974996 2022-03-29
LOTIS-8
ADC Therapeutics S.A.
Phase 1 Withdrawn
NCT04893915 2022-03-11
Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
Washington University School of Medicine
Phase 2 Withdrawn
NCT04038489 2021-11-22
Breast 51
University of Virginia
Phase 2 Withdrawn
NCT00006669 2021-10-27
Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma
Medstar Health Research Institute
Phase 2 Withdrawn
NCT02441270 2021-07-13
Evaluation of the Immunological Effects of a Combined Treatment With Radiation and Cyclophosphamide in Metastasized Breast Cancer Patients
University Hospital, Ghent
Phase EARLY_PHASE1 Withdrawn
NCT04067102 2021-07-09
Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC
Hebei Medical University Fourth Hospital
Phase NA Withdrawn